Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in from biologics discovery and development through to production and supply chain management.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Proteins & Antibodies

No More Hold-Ups: FDA Lifts Hold on Parkinson’s Drug

The FDA has repealed the hold placed on clinical trials for the Parkinson’s drug IkT-148009, which began in November.
Read More
Proteins & Antibodies

FDA Grant Approval for Alzheimer's Drug Leqembi

The US regulators have approved Eisai and Biogen’s Alzheimer’s drug, lecanemab, a “landmark” moment for the disease.
Read More
Proteins & Antibodies

Roche Fail to Follow in Eisai’s Footsteps: Alzheimer’s Drug Flunks Phase III Trials

Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.
Read More
Proteins & Antibodies

Heart-to-Heart or Head-to-Head: Amgen Heart Drug to Challenge Novartis

New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.
Read More
Proteins & Antibodies

AbbVie Ditch Phase II Autoimmune Drug

AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva
Read More
Proteins & Antibodies

Oxford Global's R&D Key 40 Stories 2022

Download a copy of the R&D Key 40 Stories 2022 eBook today.
Read More
Proteins & Antibodies

The STING in Immunotherapy’s Tail

Research from the University of North Carolina into STING agonists provides new insights for immunotherapy cancer treatments.
Read More
Proteins & Antibodies

Eisai’s Alzheimer's Drug Offers New Hope

Eisai’s new drug lecanemab has shown small but significant benefits for people with early Alzheimer’s disease.
Read More
Proteins & Antibodies

Is Your WASH Causing Inflammation? Protein Complex Linked to Inflammatory Conditions

Research published by the Scripps Research Institute reveals the WASH protein complex as a crucial factor in neutrophil-triggered inflammation.
Read More
Proteins & Antibodies

AstraZeneca Suffers Sales Decline for COVID Med Evusheld

A 24 million loss has been reported for the preventative COVID-19 treatment.
Read More
Proteins & Antibodies

Market Battle for Rare Disease Treatment

Argenx and AstraZeneca are set to become market rivals in their general myasthenia gravis (gMG) treatments, analysts claim.
Read More
Proteins & Antibodies

Widening the Therapeutic Window: Development of Antibody Drug Conjugates for Solid Tumours

Compared to non-solid tumours, solid tumours are more difficult to treat with conventional therapeutic methods. Antibody drug conjugates – biopharmaceutical drugs designed as a targeted therapy for treating cancer – represent a viable treatment alternative.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics